106 related articles for article (PubMed ID: 10840515)
1. Troglitazone withdrawn from market.
Am J Health Syst Pharm; 2000 May; 57(9):834. PubMed ID: 10840515
[No Abstract] [Full Text] [Related]
2. Advisory panel hears contradictory evidence, backs keeping troglitazone on market.
Miller JL
Am J Health Syst Pharm; 1999 May; 56(9):840, 842. PubMed ID: 10344603
[No Abstract] [Full Text] [Related]
3. The FDA: protector or puppet?
Terpening CM
Pharmacotherapy; 2000 Jul; 20(7):860-1. PubMed ID: 10907979
[No Abstract] [Full Text] [Related]
4. Update in endocrinology.
Whitcomb RW
Ann Intern Med; 1998 May; 128(10):871. PubMed ID: 9599203
[No Abstract] [Full Text] [Related]
5. Diabetes drug withdrawn after reports of hepatic events.
Wise J
BMJ; 1997 Dec; 315(7122):1564. PubMed ID: 9437272
[No Abstract] [Full Text] [Related]
6. Troglitazone-induced liver failure: a case study.
Graham DJ; Green L; Senior JR; Nourjah P
Am J Med; 2003 Mar; 114(4):299-306. PubMed ID: 12681458
[TBL] [Abstract][Full Text] [Related]
7. Hepatotoxicity of the thiazolidinediones.
Tolman KG; Chandramouli J
Clin Liver Dis; 2003 May; 7(2):369-79, vi. PubMed ID: 12879989
[TBL] [Abstract][Full Text] [Related]
8. Drugs and disease.
SoRelle R
Circulation; 2000 Apr; 101(13):E9027-8. PubMed ID: 10747361
[No Abstract] [Full Text] [Related]
9. Rezulin to be withdrawn from the market.
Diabetes Technol Ther; 2000; 2(2):289. PubMed ID: 11469272
[No Abstract] [Full Text] [Related]
10. Drug recalls underscore safety concerns.
Greene HL
Health News; 2000 May; 6(5):4. PubMed ID: 10851966
[No Abstract] [Full Text] [Related]
11. FDA drug-review, surveillance processes under scrutiny.
Miller JL
Am J Health Syst Pharm; 1999 Mar; 56(5):404, 406, 408. PubMed ID: 10096696
[No Abstract] [Full Text] [Related]
12. Liver enzyme monitoring in patients treated with troglitazone.
Graham DJ; Drinkard CR; Shatin D; Tsong Y; Burgess MJ
JAMA; 2001 Aug; 286(7):831-3. PubMed ID: 11497537
[TBL] [Abstract][Full Text] [Related]
13. Troglitazone-associated hepatic failure.
Misbin RI
Ann Intern Med; 1999 Feb; 130(4 Pt 1):330. PubMed ID: 10068399
[No Abstract] [Full Text] [Related]
14. Troglitazone-associated hepatotoxicity treated successfully with steroids.
Prendergast KA; Berg CL; Wisniewski R
Ann Intern Med; 2000 Nov; 133(9):751. PubMed ID: 11074925
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of troglitazone for lipodystrophy syndromes.
Caldwell SH
Ann Intern Med; 2001 May; 134(10):1008. PubMed ID: 11352703
[No Abstract] [Full Text] [Related]
16. A Japanese case of liver dysfunction after 19 months of troglitazone treatment.
Iwase M; Yamaguchi M; Yoshinari M; Okamura C; Hirahashi T; Tsuji H; Fujishima M
Diabetes Care; 1999 Aug; 22(8):1382-4. PubMed ID: 10480795
[No Abstract] [Full Text] [Related]
17. Rapid-onset subfulminant liver failure associated with troglitazone.
Jagannath S; Rai R
Ann Intern Med; 2000 Apr; 132(8):677. PubMed ID: 10766693
[No Abstract] [Full Text] [Related]
18. Troglitazone (Rezulin) and hepatic injury.
Faich GA; Moseley RH
Pharmacoepidemiol Drug Saf; 2001; 10(6):537-47. PubMed ID: 11828837
[TBL] [Abstract][Full Text] [Related]
19. Severe hepatotoxicity associated with troglitazone.
Herrine SK; Choudhary C
Ann Intern Med; 1999 Jan; 130(2):163-4. PubMed ID: 10068372
[No Abstract] [Full Text] [Related]
20. From the Food and Drug Administration.
JAMA; 2000 May; 283(17):2228. PubMed ID: 10807369
[No Abstract] [Full Text] [Related]
[Next] [New Search]
